- Trials with a EudraCT protocol (22)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
22 result(s) found for: RNA world.
Displaying page 1 of 2.
EudraCT Number: 2016-001371-69 | Sponsor Protocol Number: EVITAs | Start Date*: 2016-09-30 |
Sponsor Name:Fundació Lluita contra la SIDA | ||
Full Title: Tenofovir DP concentrations in seminal cells and semen quality in HIV-1 infected patients receiving a TAF containing regimen | ||
Medical condition: HIV-1 positive patients | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001656-35 | Sponsor Protocol Number: 109MS408 | Start Date*: 2014-04-07 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects with Relapsing-Remitting Multipl... | ||||||||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) HU (Completed) BE (Completed) PT (Completed) IT (Completed) CZ (Completed) SK (Completed) ES (Completed) SI (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004158-17 | Sponsor Protocol Number: GELTAMO-IMCL-2015 | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:GELTAMO (Grupo Cooperativo Español de Llinfoma/Trasplante Autólogo de Médula Ósea) | |||||||||||||
Full Title: Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma. | |||||||||||||
Medical condition: Mantle Cell Lyphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002313-41 | Sponsor Protocol Number: CRC2021-02 | Start Date*: 2023-06-06 | ||||||||||||||||
Sponsor Name:CENTRO RICERCHE CLINICHE DI VERONA | ||||||||||||||||||
Full Title: A PHASE 2, MULTICENTER, OPEN LABEL, CLINICAL TRIAL EVALUATING SAFETY AND ACTIVITY OF NIVOLUMAB/IPILIMUMAB AND CHEMOTHERAPY COMBINATION IN ADVANCED NSCLC PATIENTS WITH HIV, HBV, HCV AND POST-ACUTE S... | ||||||||||||||||||
Medical condition: advanced non-small-cell lung cancer (NSCLC) (both squamous and non-squamous) in patients with chronic viral infections or sequalae from Sars-Cov2 infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001984-35 | Sponsor Protocol Number: M16OPN | Start Date*: 2017-06-22 | |||||||||||
Sponsor Name:Antoni van leeuwenhoek ziekenhuis | |||||||||||||
Full Title: Multicenter Phase 2 Study to Identify of the Optimal neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo) | |||||||||||||
Medical condition: Patients with stage III melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001349-37 | Sponsor Protocol Number: COVID-19-HBO | Start Date*: 2020-05-08 |
Sponsor Name:Karolinska Institutet | ||
Full Title: A Randomized, Controlled, Open Label, Multicentre Clinical Trial to explore Safety and Efficacy of Hyperbaric Oxygen for preventing ICU admission, Morbidity and Mortality in Adult Patients With CO... | ||
Medical condition: COVID-19 (SARS-CoV-2) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004620-38 | Sponsor Protocol Number: DOLU-FAT | Start Date*: 2020-04-09 | |||||||||||
Sponsor Name:Fundació Lluita contra la SIDA | |||||||||||||
Full Title: Study to assess the effect of a Darunavir/Cobicistat-based regimen on weight and body composition in HIV-infected subjects who present weight gain during a dolutegravir-based regimen. | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002822-19 | Sponsor Protocol Number: B1371019 | Start Date*: 2018-07-09 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN ... | |||||||||||||
Medical condition: ACUTE MYELOID LEUKEMIA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) SE (Completed) BE (Completed) PL (Completed) ES (Completed) DE (Completed) IT (Prematurely Ended) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002328-35 | Sponsor Protocol Number: CANTABRICO | Start Date*: 2020-11-11 | |||||||||||
Sponsor Name:AstraZeneca Farmacéutica Spain, S.A | |||||||||||||
Full Title: A Phase IIIB, Single Arm Study, of Durvalumab in Combination with Platinum-Etoposide for Untreated Patients with Extensive-Stage Small Cell Lung Cancer reflecting Real World Clinical Practice in Sp... | |||||||||||||
Medical condition: Extensive-Stage Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005951-19 | Sponsor Protocol Number: APL-D-003-20 | Start Date*: 2021-06-08 | |||||||||||
Sponsor Name:Pharma Mar, S.A. | |||||||||||||
Full Title: A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patients Requiring Hospitalisation for Management... | |||||||||||||
Medical condition: moderate COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BG (Prematurely Ended) GR (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005225-81 | Sponsor Protocol Number: VALYM | Start Date*: 2021-04-28 | ||||||||||||||||
Sponsor Name:LYSARC | ||||||||||||||||||
Full Title: A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA | ||||||||||||||||||
Medical condition: RELAPSE/REFRACTORY B-CELL LYMPHOMA | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000197-30 | Sponsor Protocol Number: UoL001289 | Start Date*: 2018-07-13 |
Sponsor Name:The University of Liverpool | ||
Full Title: Sodium Valproate for Epigenetic Reprogramming in the Management of High Risk Oral Epithelial Dysplasia | ||
Medical condition: High Risk Oral Epithelial Dysplasia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001074-30 | Sponsor Protocol Number: N20MAT | Start Date*: 2020-06-26 | ||||||||||||||||||||||||||
Sponsor Name:Netherlands cancer institute (NKI) Antioni van Leeuwenhoek (AvL) | ||||||||||||||||||||||||||||
Full Title: Neo-adjuvant nivolumab or nivolumab with ipilimumab in advanced cutaneous squamous cell carcinoma patients prior to standard of care surgery; the MATISSE trial | ||||||||||||||||||||||||||||
Medical condition: Primary or recurrent stage III-IVA cutaneous squamous cell carcinoma of all body sites OR tage I-II cutaneous squamous cell carcinoma, only in the case of: • Presence of multifocal disease for wh... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000207-36 | Sponsor Protocol Number: 275AS101 | Start Date*: 2020-11-18 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 ... | ||||||||||||||||||
Medical condition: ALS and ALS associated with ataxin-2 (ATXN2) poly-CAG expansion (polyQ-ALS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000140-58 | Sponsor Protocol Number: NL7255100000 | Start Date*: 2020-07-23 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Complement Inhibition: Attacking the Overshooting Inflammation @fter Traumatic Brain Injury - A phase II trial on the safety and efficacy of C1 esterase inhibitor Cinryze for the acute management o... | |||||||||||||
Medical condition: Severe traumatic Brain Injury (TBI) with GCS < 13 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007587-21 | Sponsor Protocol Number: CLL10 | Start Date*: 2008-09-05 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocyti... | |||||||||||||
Medical condition: patients (age 18 years or older) with chronic lymphocytic leukemia: Stage Binet C or stage Binet B and A requiring treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) DK (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004306-50 | Sponsor Protocol Number: A4001050 | Start Date*: 2007-04-23 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) BE (Completed) CZ (Completed) DE (Completed) PT (Completed) ES (Completed) NL (Completed) AT (Completed) GR (Completed) IT (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001672-38 | Sponsor Protocol Number: KRT-232-102 | Start Date*: 2018-12-10 | |||||||||||
Sponsor Name:Kartos Therapeutics, Inc. | |||||||||||||
Full Title: A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemi... | |||||||||||||
Medical condition: Phlebotomy-dependent polycythemia vera. Polycythemia Vera (PV) is classified as a myeloproliferative neoplasm (MPN). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Prematurely Ended) ES (Ongoing) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021091-28 | Sponsor Protocol Number: AB10004 | Start Date*: 2014-12-18 | |||||||||||
Sponsor Name:AB Science | |||||||||||||
Full Title: A multicenter, randomised, open-label, three-parallel groups, phase 2-3 study to evaluate the efficacy and safety of masitinib with dexamethasone, gemcitabine with dexamethasone and the combination... | |||||||||||||
Medical condition: Relapsed or refractory Peripheral T-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GR (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) SK (Prohibited by CA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001302-30 | Sponsor Protocol Number: ACOVACT | Start Date*: 2020-04-15 | ||||||||||||||||||||||||||
Sponsor Name:Medical University of Vienna | ||||||||||||||||||||||||||||
Full Title: A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute re... | ||||||||||||||||||||||||||||
Medical condition: Infection with SARS-COV-2 (=COVID-19) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
